oncology guideline presentation
TRANSCRIPT
![Page 1: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/1.jpg)
www.adaevidencelibrary.com
OncologyEvidence-Based Nutrition Practice Guidelines
Executive Summary of Recommendations
American Dietetic AssociationEvidence Analysis Library®
www.adaevidencelibrary.com
![Page 2: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/2.jpg)
Definition
What is Evidence-based Dietetics Practice?
“Evidence-Based Dietetics Practice is the use of systematically reviewed scientific evidence in making food and nutrition practice decisions by integrating best available evidence with professional expertise and client values to improve outcomes.”
ADA Scope of Dietetics Practice Framework: Approved by ADA House of Delegates
© 2008 ADA Evidence Analysis Library® 2
![Page 3: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/3.jpg)
Overall Guideline Objective
To provide Medical Nutrition Therapy (MNT) guidelines aimed at managing symptoms, preventing weight loss and maintaining optimal nutritional status during cancer treatment.
3(c) 2008 American Dietetic Association
![Page 4: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/4.jpg)
Target PopulationAdult (19 to 44 years)Middle Age (45 to 64 years)Aged (65 to 79 years)Male and Female
Target Population DescriptionAdults who are receiving oncology treatment or care.
4(c) 2008 American Dietetic Association
![Page 5: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/5.jpg)
Guideline Narrative OverviewThe focus of this guideline is on oncology nutrition practice during the treatment of adult patients with cancer.
Cancer is a complex multifactoral chronic disease that develops from an interaction between genetics and the environment. Treatment of cancer and nutrition impact symptoms should be based on a comprehensive nutrition assessment to maximize adequate intake and identify interventions. The goals of nutrition care to prevent or reverse nutrient deficiencies, preserve lean body mass, help patients better tolerate treatments, and minimize nutrition-related side effects and complications.
5(c) 2008 American Dietetic Association
![Page 6: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/6.jpg)
Medical Nutrition Therapy and Oncology
Scientific evidence supports the effectiveness of nutrition therapy to increase effectiveness of oncology therapy and to reduce nutrition impact symptoms among individuals who have cancer. Topics included in this guideline are:
Use of medical nutrition therapy and dietitian intervention Determination of RMR in cancer patients Use of enteral and parenteral nutrition in cancer patients Use of oral vitamin and antioxidant supplements Use of omega-3 fatty acid-enhanced medical food supplement and oral supplements and EPA-enhanced medical food supplement and fish oil supplements.
The registered dietitian plays an integral role on the interdisciplinary healthcare team by making the optimal nutrition prescription and developing the nutrition intervention plan for patients undergoing cancer therapy.
6(c) 2008 American Dietetic Association
![Page 7: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/7.jpg)
Evidence-based nutrition practice guidelines are developed to help dietetic practitioners, patients and consumers make shared decisions about health care choices in specific clinical circumstances. If properly developed, communicated and implemented, guidelines can improve care.
© 2008 ADA Evidence Analysis Library® 7
Statement of Intent
![Page 8: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/8.jpg)
While ADA evidence-based nutrition practice guidelines represent a statement of best practice based on the latest available evidence at the time of publishing, they are not intended to overrule professional judgment. Rather, they may be viewed as a relative constraint on individual clinician discretion in a particular clinical circumstance. The independent skill and judgment of the health care provider must always dictate treatment decisions. These nutrition practice guidelines are provided with the express understanding that they do not establish or specify particular standards of care, whether legal, medical or other.
© 2008 ADA Evidence Analysis Library® 8
Disclaimer
![Page 9: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/9.jpg)
ADA OncologyEvidence Based
Nutrition Practice GuidelineExecutive Summary
9© 2008 ADA Evidence Analysis Library®
![Page 10: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/10.jpg)
Guideline Rating
Each Recommendation is Rated:• Strong,• Fair,• Weak,• Consensus, or• Insufficient Evidence
Each Recommendation Statement is:• Conditional or• Imperative
© 2008 ADA Evidence Analysis Library® 10
![Page 11: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/11.jpg)
11
Statement RatingStatement Rating DefinitionDefinition Implication for PracticeImplication for Practice
Strong A Strong recommendation means that the workgroup believes that the benefits of the recommended approach clearly exceed the harms (or that the harms clearly exceed the benefits in the case of a strong negative recommendation), and that the quality of the supporting evidence is excellent/good (grade I or II).* In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms.
Practitioners should follow a Strong recommendation unless a clear and compelling rationale for an alternative approach is present.
Fair A Fair recommendation means that the workgroup believes that the benefits exceed the harms (or that the harms clearly exceed the benefits in the case of a negative recommendation), but the quality of evidence is not as strong (grade II or III).* In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms.
Practitioners should generally follow a Fair recommendation but remain alert to new information and be sensitive to patient preferences.
Recommendation Ratings (1 of 2)
© 2008 ADA Evidence Analysis Library®
![Page 12: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/12.jpg)
12
Statement RatingStatement Rating DefinitionDefinition Implication for PracticeImplication for Practice
Weak A Weak recommendation means that the quality of evidence that exists is suspect or that well-done studies (grade I, II, or III)* show little clear advantage to one approach versus another..
Practitioners should be cautious in deciding whether to follow a recommendation classified as Weak, and should exercise judgment and be alert to emerging publications that report evidence. Patient preference should have a substantial influencing role.
Consensus A Consensus recommendation means that Expert opinion (grade IV) supports the guideline recommendation even though the available scientific evidence did not present consistent results, or controlled trials were lacking.
Practitioners should be flexible in deciding whether to follow a recommendation classified as Consensus, although they may set boundaries on alternatives. Patient preference should have a substantial influencing role.
Insufficient Evidence An Insufficient Evidence recommendation means that there is both a lack of pertinent evidence (grade V)* and/or an unclear balance between benefits and harms.
Practitioners should feel little constraint in deciding whether to follow a recommendation labeled as Insufficient Evidence and should exercise judgment and be alert to emerging publications that report evidence that clarifies the balance of benefit versus harm. Patient preference should have a substantial influencing role.
Recommendation Ratings (2 of 2)
© 2008 ADA Evidence Analysis Library®
![Page 13: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/13.jpg)
• Conditional statements clearly define a specific situation and contain conditional text that would limit their applicability to specified circumstances, or to a sub-population group. More specifically, a conditional recommendation can be stated in if/then terminology.• e.g., If an individual does not eat food sources of omega-3 fatty
acids, then 1g of EPA and DHA omega-3 fatty acid supplements may be recommended for secondary prevention.
• Imperative recommendations are broadly applicable to the target population and are stated as “require,” or “must,” or “should achieve certain goals.” • e.g., Portion control should be included as part of a
comprehensive weight management program. Portion control at meals and snacks results in reduced energy intake and weight loss.
© 2008 ADA Evidence Analysis Library® 13
Conditional/Imperative
![Page 14: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/14.jpg)
© 2008 ADA Evidence Analysis Library®
Oncology Guideline Topics
14
BreastChemotherapyAuto-HCTRadiation
ColorectalEsophageal Head and Neck
RadiationSurgery
HematologicalLungPancreatic
![Page 15: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/15.jpg)
Executive Summary of Recommendations
Oncology
![Page 16: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/16.jpg)
Breast Cancer
ADA Oncology Evidence Based Nutrition Practice Guideline
(c) 2008 American Dietetic Association
![Page 17: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/17.jpg)
17
Oncology - Breast cancer
Use of indirect calorimetry to measure REE is more accurate than estimation in early stage and advanced metastatic breast cancer patients. If measurement of REE is not possible or not thought to be imperative, use the HBE to estimate calorie requirements. Limited evidence indicates that the mean estimated REE was comparable to measured REE in these populations. No research was available to compare HBE using individual error or to compare HBE with other predictive equations in these populations.
WeakImperative
Determination of REE and Chemotherapy
![Page 18: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/18.jpg)
18
Oncology - Breast cancer
Use of an oral arginine supplement to improve long-term clinical response for patients with breast cancer prior to the start of neoadjuvant chemotherapy is not currently recommended. Evidence is not available to evaluate the safety of arginine or its effect on cancer symptoms for patients with breast cancer receiving chemotherapy. One RCT demonstrated a statistically significant histopathological response in tumor sizes less than 6 cm, however there was no improvement in short-term clinical response.
WeakImperative
Arginine and Chemotherapy
![Page 19: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/19.jpg)
19
Oncology - Breast cancer
Parenteral nutrition (PN) should not be routinely recommended for breast cancer patients undergoing auto-HCT who are well-nourished prior to treatment. While PN may preserve nutritional status and lean body mass in these patients, it does not appear to affect LOS or survival, and may increase risk of infectious complications.
WeakImperative
Auto-HCT and PN
![Page 20: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/20.jpg)
20
Oncology - Breast cancer
If vitamin E (alpha tocopherol, 670-1000 mg) oral supplement is proposed to promote tolerance or reduce late-effects of radiation, advise that no research is available on the impact of vitamin E supplementation to promote tolerance of radiation. Evidence is inconclusive on the benefit of vitamin E for treatment of chronic radiation-induced fibrosis. Vitamin E supplementation may have adverse effects such as nutrient-nutrient interactions, drug-nutrient interactions (e.g., anti-coagulant and anti-hypertensive medications/herbal supplements) and disease-related complications.
WeakCondit ional
Vitamin E and Radiation
![Page 21: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/21.jpg)
Colorectal Cancer
ADA Oncology Evidence Based Nutrition Practice Guideline
(c) 2008 American Dietetic Association
![Page 22: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/22.jpg)
22
Oncology - Colorectal cancer
Dietitians should provide weekly Medical Nutrition Therapy (MNT) that includes an individualized nutrition prescription and counseling for patients with colorectal cancer undergoing pelvic radiation. Individualized counseling with a focus on the consumption of regular foods may improve calorie and protein intake, nutrition status, quality of life (QOL) and reduce symptoms of anorexia, nausea, vomiting and diarrhea.
FairImperative
Radiation and MNT
![Page 23: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/23.jpg)
Esophageal Cancer
ADA Oncology Evidence Based Nutrition Practice Guideline
(c) 2008 American Dietetic Association
![Page 24: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/24.jpg)
24
Oncology-Esophageal cancer
The Dietitian should provide Medical Nutrition Therapy (MNT) consisting of a pre-treatment evaluation and weekly visits for six weeks during chemoradiation treatment for esophageal cancer to improve outcomes. MNT may reduce the amount of weight loss, unplanned hospitalizations, LOS, as well as improves tolerance to treatment and the likelihood of receiving prescribed radiation dose.
WeakImperative
Chemoradiation and MNT
![Page 25: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/25.jpg)
25
Oncology - Esophageal cancer
Enteral nutrition (EN) may be used to increase calorie and protein intake in esophageal cancer patients undergoing chemoradiation therapy. EN has been shown to maintain weight, however EN has not been shown to improve tolerance to therapy or survival.
WeakImperative
Chemoradiation and use of enteral nutrition
![Page 26: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/26.jpg)
26
Oncology - Esophageal cancer
Use of parenteral nutrition (PN) to prevent weight loss or improve effectiveness of treatment for patients with esophageal cancer receiving chemoradiation therapy(CRT) is not recommended. PN has not been shown to prevent weight loss or improve effectiveness of treatment, even though patients were able to tolerate a higher dose of CRT. PN may have adverse effects such as complications related to refeeding syndrome, inadequate glycemic control and increased risk of infections.
WeakImperative
Use of parenteral nutrition and chemoradiation
![Page 27: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/27.jpg)
Head and Neck Cancer
ADA Oncology Evidence Based Nutrition Practice Guideline
(c) 2008 American Dietetic Association
![Page 28: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/28.jpg)
Chemoradiation and Determination of REE
Use of indirect calorimetry to measure Resting Energy Expenditure (REE) is more accurate than estimation in patients with advanced head and neck cancer undergoing chemoradiation therapy. If measurement of REE is not possible or not thought to be imperative, use the Harris Benedict Equation (HBE) to estimate calorie needs. However, limited evidence indicates that HBE underestimates REE in this population.
WeakImperative
© 2008 ADA Evidence Analysis Library® 28
ONC – Head and neck cancer
![Page 29: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/29.jpg)
Medical Food Supplements and Radiation
Dietitians should consider use of medical food supplements (MFS) to improve protein and calorie intake for patients with head and neck cancer undergoing radiation therapy. Use of MFS may be associated with fewer treatment interruptions, a reduction of mucosal damage, and may minimize weight loss.
FairImperative
© 2008 ADA Evidence Analysis Library® 29
ONC – Head and neck cancer
![Page 30: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/30.jpg)
Medical Nutrition Therapy (MNT) and radiation therapy
Medical Nutrition Therapy (MNT) that consists of nutrition assessment, intensive intervention, and ongoing monitoring and evaluation by an RD should be provided for patients with head/neck cancer being considered for radiation therapy. MNT has been shown to improve calorie and protein intake, maintain anthropometric measurements and improve quality of life (QOL).
StrongImperative
© 2008 ADA Evidence Analysis Library® 30
ONC – Head and neck cancer
![Page 31: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/31.jpg)
Medical Nutrition Therapy (MNT) and pre-treatment evaluation
The Dietitian should provide MNT consisting of a pre-treatment evaluation and weekly visits during radiation treatment for head and neck cancer to improve outcomes.
StrongImperative
© 2008 ADA Evidence Analysis Library® 31
ONC – Head and neck cancer
![Page 32: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/32.jpg)
Radiation and use of EN
Use enteral nutrition (EN) to increase calorie and protein intake for outpatients with stage III or IV head and neck cancer undergoing intensive radiation treatment. Maintenance of nutritional status by EN during radiation therapy may improve tolerance of therapy to promote better outcomes.
StrongImperative
© 2008 ADA Evidence Analysis Library® 32
ONC – Head and neck cancer
![Page 33: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/33.jpg)
Use of honey and radiationIf the topical use of honey is proposed to prevent mouth
sores caused by radiation treatment for patients with head and neck cancer, advise that its use may or may not be beneficial. Limited evidence shows that topical use of honey has been associated with decreased incidence of severe mucositis, weight gain and reduced treatment interruptions; however, the risks of interference with effectiveness of radiation treatment and infectious complications were not evaluated.
WeakCondit ional
© 2008 ADA Evidence Analysis Library® 33
ONC – Head and neck cancer
![Page 34: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/34.jpg)
Use of vitamin E oral supplementUse of vitamin E oral supplements to enhance efficacy,
improve tolerance and reduce late-effects of radiation therapy for patients with head/neck cancer is not recommended. While limited evidence supports the use of vitamin E oral supplements to reduce late effects(osteoradionecrosis), there is strong research reporting an increased risk for second primary cancers and decreased survival rate with use of vitamin E in doses greater than or equal to 400 IU (268mg).
WeakImperative
© 2008 ADA Evidence Analysis Library® 34
ONC – Head and neck cancer
![Page 35: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/35.jpg)
Post-operative use of arginineThe Post-operative use of arginine-enhanced medical
food supplements (MFS) or enteral nutrition (EN) to improve outcomes for patients with head and neck cancer is not recommended. Arginine-enhanced versus non-arginine-enhanced MFS and EN did not produce significant changes in weight and body composition in either well-nourished or malnourished subjects. Most evidence shows there is no impact of arginine-enhanced MFS or EN on immune function. Limited research reported that arginine-enhanced EN can improve post-operative complications and LOS in malnourished patients.
FairImperative
© 2008 ADA Evidence Analysis Library® 35
ONC – Head and neck cancer
![Page 36: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/36.jpg)
Pre-operative use of arginine-enhanced EN to improve outcomes for patients with head and neck cancer is not recommended. No significant improvement in clinical outcomes, nutritional status, or surgery-induced immune suppression was observed among malnourished compared to patients receiving a non-enhanced EN, or those who did not receive EN.
FairImperative
© 2008 ADA Evidence Analysis Library® 36
ONC – Head and neck cancer
Pre-operative use of arginine
![Page 37: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/37.jpg)
Surgery and EPA-enhanced medical food supplement
If the use of an EPA-enhanced MFS is proposed to decrease post-surgical complications (e.g., infections and weight loss) for oral and laryngeal cancer patients, advise inadequate evidence exists to show a benefit. While one study comparing EPA- versus arginine-enhanced MFS found that an EPA supplement led to an increase in weight, there were no differences in fat-free mass or infectious complications.
WeakCondit ional
© 2008 ADA Evidence Analysis Library® 37
ONC – Head and neck cancer
![Page 38: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/38.jpg)
Hematological Cancer
ADA Oncology Evidence Based Nutrition Practice Guideline
(c) 2008 American Dietetic Association
![Page 39: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/39.jpg)
39
Onc – Hematological Cancer
Medical Nutrition Therapy (MNT) that consists of nutrition assessment, intensive intervention, and ongoing monitoring and evaluation by a registered dietitian may be of benefit to patients with acute leukemias undergoing chemotherapy. Daily monitoring of intake and incorporating patient preferences have been shown to increase nutrition intake which positively affects body weight and tumor-therapy side effects (e.g., fatigue and anorexia).
WeakImperative
Chemotherapy and MNT
![Page 40: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/40.jpg)
Lung Cancer
ADA Oncology Evidence Based Nutrition Practice Guideline
(c) 2008 American Dietetic Association
![Page 41: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/41.jpg)
41
Onc - Lung cancer
Use of indirect calorimetry to measure REE is more accurate than estimation in patients with non-small cell lung cancer (NSLC) cancer undergoing chemotherapy. If measurement of REE is not possible or not thought to be imperative, use HBE to estimate calorie needs. However, limited evidence indicates that the HBE may underestimate energy needs by an average of 12-13%.
WeakImperative
Chemotherapy and Determination of REE
![Page 42: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/42.jpg)
42
Onc - lung cancer
The use of antioxidants (vitamin C, vitamin E, beta-carotene, selenium) above the tolerable upper intake level to improve treatment outcomes in patients with advanced non-small cell lung cancer undergoing chemotherapy is not recommended. In this population, use of high-dose multiple oral antioxidants did not significantly influence response to treatment, survival, survival time and toxicity. More studies are needed.
WeakImperative
Chemotherapy and use of Antioxidant Supplements
![Page 43: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/43.jpg)
43
Onc - lung cancer
Medical Nutrition Therapy (MNT) that consists of nutrition assessment, intensive intervention, and ongoing monitoring and evaluation by an RD may be of benefit to patients with small cell lung cancer undergoing chemotherapy. Providing MNT may improve protein and calorie intake, which has been shown to improve weight status and QOL.
WeakImperative
MNT and Chemotherapy
![Page 44: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/44.jpg)
Pancreatic Cancer
ADA Oncology Evidence Based Nutrition Practice Guideline
![Page 45: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/45.jpg)
45
Onc - Pancreatic cancer
Use of omega-3 fatty acids to alter the prolonged acute-phase response is not recommended for pancreatic cancer patients. Consumption of an omega-3 fatty acid-enhanced medical food supplement (mean dose 2.2g daily) or an oral supplement (2g EPA daily) for pancreatic cancer patients experiencing weight loss has not been shown to reduce serum CRP concentrations after 12 weeks of EPA supplementation and there are potential drug-nutrient interactions (e.g., anti-coagulant and anti-hypertensive medications/herbal supplements).
FairImperative
Use of omega-3 supplements for weight loss
![Page 46: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/46.jpg)
46
Onc-Pancreatic cancer
Use of supplemental omega-3 fatty acids for anticachetic effects leading to changes in body composition (e.g., increase in LBM, weight gain or weight stabilization) is not recommended for patients with pancreatic cancer. EPA as a capsule or in a medical food supplement was not associated with an increase in LBM. Evidence that fish oil supplements stabilize weight or produce weight gain is inconclusive. There are potential drug-nutrient interactions (e.g., anti-coagulant and anti-hypertensive medications/herbal supplements).
StrongImperative
Use of omega-3 supplements for anticachetic effects
![Page 47: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/47.jpg)
Oncology (ONC)
Algorithm
47© 2008 ADA Evidence Analysis Library®
![Page 48: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/48.jpg)
48
Oncology Algorithms
Nutrition AssessmentNutrition DiagnosisNutrition Intervention: CancerMonitoring and Evaluatiion
Algorithms are available online: www.adaevidencelibrary.com
Evidence Based Guidelines > Guideline List > Oncology > Algorithms
![Page 49: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/49.jpg)
49
AssessmentDiagnosisIntervention Monitor/Evaluation
Oncology Algorithm (online)
Follows the NutritionCare Process (NCP)
Blue shaded itemsLink to GuidelineRecommendationPages (online)
Example
![Page 50: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/50.jpg)
50
Oncology Team Members
• Christina W. Biesemeier, MS, RD, LD, FADA, LDN (co- chair) • Laura G. Elliott, MPH, RD, LD, (co- chair) • Carol B. Frankmann, MS, RD, LD, CNSD • Dianne E. Kiyomoto-Kuey, RD • Kimberly Robien, PhD, RD, FADA, CNSD • Denise Snyder, MS, RD, LDN
Former Work Group Member• Sandra Luthringer, RD, LDN
Project Manager• Tami A. Piemonte, MS, RD, LD
Evidence Based Nutrition Practice Guideline Workgroup Committee
![Page 51: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/51.jpg)
No Implied EndorsementNo endorsement by the American Dietetic Association of
any brand-name product or service is intended or should be inferred from a Guideline or from any of its components (including Question, Evidence Summary, Conclusion Statement, Conclusion Statement Grade, Recommendation or Recommendation Rating).
• Evidence-based Nutrition Practice Guidelines are intended to serve as a synthesis of the best evidence available to inform registered dietitians as they individualize nutrition care for their clients. Guidelines are provided with the express understanding that they do not establish or specify particular standards of care, whether legal, medical or other.
• Evidence-based Nutrition Practice Guidelines are intended to summarize best available research as a decision tool for ADA members.
© 2008 ADA Evidence Analysis Library® 51
![Page 52: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/52.jpg)
Citation
Evidence-based Nutrition Practice Guideline on Oncology published at www.adaevidencelibrary.com and copyrighted by the American Dietetic Association; accessed on December 10, 2008.
© 2008 ADA Evidence Analysis Library® 52
![Page 53: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/53.jpg)
What are Evidence-Based Toolkits?
Set of companion documents for application of the practice guideline
Disease or condition specific Include:
• documentation forms• outcomes monitoring sheets• client education resources• case studies • MNT protocol for treatment of
disease/condition Incorporate Nutrition Care Process as
the standard process care
53
![Page 54: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/54.jpg)
DLM ToolkitPurchase the companion materials for applying the DLM Evidence-Based Nutrition Practice Guideline (42 files, 300 pages) in the online EAL Store.
Includes:•MNT Protocol•Documentation forms•Client education resources•Outcomes management forms
54
![Page 55: Oncology guideline presentation](https://reader034.vdocument.in/reader034/viewer/2022042817/559f55721a28ab05088b45f8/html5/thumbnails/55.jpg)
For additional information:
ADA Evidence Analysis Library®
www.adaevidencelibrary.com
55© 2008 ADA Evidence Analysis Library®